Jeff Jonas joins Shire’s Leadership Team
pharmafile | November 15, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Jeff Jonas, Shire
Shire has announced that Jeff Jonas has been appointed president of Shire’s Regenerative Medicine (RM) business and will join the firm’s Leadership Team.
After a varied career in R&D, commercial and entrepreneurial business roles, Jonas joined Shire in July 2008 as leader of the Speciality Pharmaceuticals (SP) Research & Development team.
Jonas who will report to Shire chief executive Angus Russell, has been closely involved with the RM business since Shire acquired it as Advanced BioHealing in June 2011. In addition to his role as head of the SP R&D team, he has been leading the RM R&D team and has been a member of the RM leadership team.
His role as head of the SP R&D team will be filled by Arnaud Partiot who is a qualified psychiatrist and has been a senior member of the Shire SP team in various clinical research & development, medical affairs and commercial roles since joining Shire in 2004.
Kevin Rakin, who led Advanced BioHealing since 2007 and during its integration into Shire, is stepping down from his position as Regenerative Medicine president and from the Shire Leadership Team to pursue new career interests. Rakin will be available to provide transitional support.
Russell said: “We are pleased with the progress we are making in transforming our Regenerative Medicine business. Jeff’s insight and experience will enable us to build on this as we shape this business for future growth. We have great ambition for this business and we’re committed to seeing those ambitions realised.”
Before joining Shire in 2008, Jonas served as executive VP at Isis Pharmaceuticals in charge of clinical and pre-clinical development, regulatory affairs, quality assurance and compliance, and had broad responsibility for the product pipeline.
Related Content
Takeda plans to vacate all 1,000 staff from US HQ by the year’s end
Takeda has announced its plans to vacate all staff from its US headquarters in Deerfield, …
Novartis buys dry eye treatment Xiidra in deal worth $5.3 billion
Japanese multinational Takeda Pharmaceutical has agreed to sell its dry eye drug Xiidra to Swiss …
Top Ten most popular articles on Pharmafile.com this week!
With the completion of Takeda’s £46 billion acquisition of Shire finally done, another even bigger …
